| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Readout Capital, LP | 9.4% | +5.6% | $4,980,934 | +$829,645 | 1,119,311 | +20% | Matthew Smith | 30 Jun 2025 |
| Bleichroeder LP | 9.69% | $4,783,750 | 1,075,000 | Bleichroeder LP | 30 Jun 2025 | |||
| Lynx1 Capital Management LP | 8.8% | -11.9% | $5,755,026 | +$1,526,501 | 1,042,596 | +36.1% | LYNX1 CAPITAL MANAGEMENT LP | 30 Sep 2025 |
| TANG CAPITAL MANAGEMENT LLC | 6.4% | $3,588,860 | 673,332 | TANG CAPITAL MANAGEMENT, LLC | 31 Mar 2025 | |||
| NOVARTIS PHARMA AG | 3.7% | -34% | $1,840,435 | 413,581 | 0% | Novartis Pharma AG | 30 Jun 2025 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 3.7% | $2,165,312 | 406,250 | Highbridge Capital Management, LLC | 31 Mar 2025 | |||
| Weinstein Benjamin | 5.2% | $2,107,956 | 395,489 | Weinstein Benjamin | 18 Mar 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 4,649,562 | $25,664,758 | +$1,234,800 | $5.52 | 54 |
| 2025 Q2 | 4,437,938 | $18,638,020 | +$2,152,791 | $4.2 | 51 |
| 2025 Q1 | 3,786,321 | $18,062,451 | +$340,769 | $4.77 | 47 |
| 2024 Q4 | 3,859,340 | $14,708,103 | -$4,075,765 | $3.81 | 51 |
| 2024 Q3 | 3,323,629 | $29,812,914 | +$1,425,206 | $8.96 | 50 |
| 2024 Q2 | 3,161,323 | $30,774,875 | -$108,215 | $9.73 | 45 |
| 2024 Q1 | 3,155,622 | $42,757,614 | +$42,755,553 | $13.56 | 40 |